# A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

> **NCT03823807** · PHASE2 · UNKNOWN · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SH-1028

## Key facts

- **NCT ID:** NCT03823807
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03
- **Primary completion:** 2020-12
- **Final completion:** 2021-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823807, "A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03823807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*